CDK4 and neoplasm: Our findings that increased cyclin D1 appears to be a universal resistance marker across all HR/HER2 subtypes suggest that cyclin D1 could be an actionable target using therapeutic approaches that promote tumor senescence or by modulating the cell cycle directly using CDK4/6 inhibitors (in the case of HER2+ tumors).40